SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate is seeing a massive surge in trading volume and investor interest as the community positions itself ahead of a critical May FDA decision for its ADHD drug, CTx-1301. Investors are actively discussing the potential impact of an anticipated U.S. patent approval on the stock, drawing parallels to previous market rallies while debating the impact of recent financing moves on the company's long-term valuation.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The VanEck Gold Miners ETF (GDX) remains a major focal point as investors debate whether mining stocks can decouple from volatile gold and silver spot prices amidst ongoing geopolitical tensions and fiscal policy shifts. The community is actively discussing Elliott Wave technical patterns, potential margin calls, and the broader macro implications of central bank activity on the metals complex.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is capturing significant trader attention as the community debates its potential inclusion in upcoming payment initiatives, despite ongoing skepticism from bears regarding its long-term price action. While some investors see the current consolidation as a prime accumulation phase for a future breakout, others remain wary of repetitive dump patterns and frequent market volatility.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is facing intense community debate as investors weigh persistent price stagnation and frustration with leadership against the potential of its long-term ecosystem development and institutional integrations. While some participants are aggressively accumulating during current price levels, others are increasingly vocal about the lack of transparent progress and the asset's failure to decouple from broader market volatility.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the stock sustains bullish momentum, driven by positive analyst upgrades and investor optimism regarding the company's expanding EV lineup and integrated AI chip technology. The community is actively debating the potential for a short squeeze as share prices test major resistance levels, with many long-term shareholders holding firm in anticipation of a significant revaluation.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is currently trending due to intensifying speculation surrounding its proprietary III-V-on-silicon photonics technology, which investors view as a critical, scalable solution for the power-efficiency bottlenecks in AI data centers. The community is actively discussing the stock's potential for high-volume commercial adoption, citing recent patent filings, government contracts, and the strategic addition of veteran industry leadership as key indicators that the company is transitioning from R&D to market-ready commercialization.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is capturing massive attention as CEO Jensen Huang unveiled a massive expansion in its AI roadmap, projecting $1 trillion in demand through 2027 and announcing new partnerships with major players like Uber to scale autonomous fleets. While the company continues to solidify its infrastructure dominance, the community is actively debating the stock's recent volatility and questioning whether the massive long-term growth targets are being overshadowed by short-term options-driven manipulation.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is currently under heavy scrutiny as investors weigh the impact of recent capital raises against anticipation for late-stage clinical trial results for its psilocybin-based treatment. While the community remains divided between those expressing frustration over share dilution and those holding for a potential long-term buyout or market-leading approval, technical traders are actively monitoring the stock's support levels as it consolidates near key psychological marks.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN Limited is currently at the center of intense debate as investors weigh the company's ambitious 4.5 GW power pipeline and projected AI revenue growth against concerns surrounding a significant $6 billion equity shelf program. While retail and institutional traders discuss potential hyperscaler partnerships and technical support levels following recent volatility, community sentiment remains split between long-term bulls betting on a pivotal AI infrastructure breakout and skeptics wary of near-term dilution and macro-driven market pressures.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investor sentiment surges following the departure of FDA official Vinay Prasad, fueling optimism that the agency will adopt a more flexible, expedited review process for the company's DMD therapy. The community is actively discussing the stock's significant move to the Nasdaq Global Select Market and high-stakes upcoming events, including a late-breaking clinical data presentation at the MDA conference and the release of quarterly financial results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TriSalus Life Sciences Inc. (TLSI) shares were in the spotlight on Thursday morning after the company’s <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.trisaluslifesci.com/news-releases/news-release-details/trisalus-life-sciences-reports-q4-and-full-year-2024-financial">fourth-quarter</a> loss exceeded Wall Street projections, but revenue topped expectations.TriSalus reported a 44% jump in its fourth-quarter (Q4) revenue to $8.3 million, higher than an analyst estimate of $8.25 million, according to FinChat data.The company’s loss per share narrowed to $0.4, compared to $1.57 in the same quarter a year ago, but it was wider than the estimated loss of $0.32.TriSalus reaffirmed its previous guidance for 2025 and said it expects sales growth of over 50% and its gross margin to exceed 87%, higher than the 86% reported for 2024. &nbsp;The oncology-focused medical technology company also said that it expects to be earnings before interest, tax, depreciation, and amortization (EBITDA) positive this year and achieve positive cash flow by the second half, extending its total cash runaway beyond this year.The company ended 2024 with $8.5 million in cash and cash equivalents.Operating expenses are also expected to reduce over 20% owing to reductions in research and development costs.On Stocktwits, retail sentiment continued to trend in the ‘extremely bearish’ territory while message volume jumped from ‘low’ to ‘high’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:649/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_at_11_02_29_AM_png_72bc5e484f.webp" alt="TLSI's Sentiment Meter and Message Volume as of 11:30 a.m. ET on March 27, 2025 | Source: Stocktwits" width="649" height="151"><figcaption>TLSI's Sentiment Meter and Message Volume as of 11:30 a.m. ET on March 27, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the company’s guidance.<stembedurl>https://stocktwits.com/FE123/message/609391420</stembedurl>Another highlighted the company’s growth in revenue.<stembedurl>https://stocktwits.com/FE123/message/609361644</stembedurl><a href="https://stocktwits.com/symbol/TLSI">TLSI shares</a> gained by over 12% this year but are down by over 40% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/new-fortress-energy-sells-jamaican-assets-to-excelerate-energy/chJ2EtuRbE4">New Fortress Energy Sells Jamaican Assets, Operations To Excelerate Energy For $1.06B: Stock Tumbles But Retail Cheers The Deal</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

TriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays Pessimistic

The company reaffirmed its previous guidance for 2025 and said it expects sales growth of over 50% and its gross margin to exceed 87%, higher than the 86% reported for 2024. 

IMFL
Invesco International Developed Dynamic Multifactor ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IMFL News

IMFLInvesco International Developed Dynamic Multifactor ETF